Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial

作者：Frederik M. Zimmermann, Victoria Y. Ding, Nico H.J. Pijls, Zsolt Piróth, Albert H.M. van Straten, L Székely, Giedrius Davidavičius, Gintaras Kalinauskas, Samer Mansour, Rajesh Kharbanda, Nikolaos Östlund-Papadogeorgos, Adel Aminian, Keith G. Oldroyd, Nawwar Al‐Attar, Nikola Jagić, Jan‐Henk E. Dambrink, Petr Kala, Oskar Angerås, Philip MacCarthy, Olaf Wendler, Filip Casselman, Nils Witt, Kreton Mavromatis, Steven E.S. Miner, Jaydeep Sarma, Thomas Engstrøm, Evald Høj Christiansen, Pim A.L. Tonino, Michael J. Reardon, Hisao Otsuki, Yuhei Kobayashi, Mark A. Hlatky, Kenneth W. Mahaffey, Manisha Desai, Y. Joseph Woo, Alan C. Yeung, Bernard De Bruyne, William F. Fearon, on behalf of the FAME 3 Investigators · 发表于：Circulation · 年份：2023 · DOI：10.1161/circulationaha.123.065770 · 被引用次数：62 · 研究领域：Coronary Interventions and Diagnostics、Cardiac and Coronary Surgery Techniques、Cerebrovascular and Carotid Artery Diseases

BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98–1.83]; P =0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6–1.7]; P =0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4–1.7]; P =0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, ...